

DAFTAR PUSTAKA

- Aleskandarany, M.A., Green, A.R., Benhasouna, A.A., et al. 2011. *Prognostic Value of Proliferation assay in the Luminal, HER2 positive, and Triple Negative biologic Classes of Breast Cancer*. Breast Cancer Res,14(1),R3.
- Brennan, P.J., et al. 2015. HER2/Neu : Mechanisms of Dimerization/ Oligomerization. Retrieved from: <http://www.nature.com/onc/journal/v19/n53/full/1203967a.html>.
- Dahlan, M.S., 2013. *Besar Sampeldan Cara Pengambilan Sampel Dalam Penelitian Kedokteran dan Kesehatan*. Edisi 5. Salemba Medika. Jakarta.
- Departemen Kesehatan Republik Indonesia. 2013. *Pemerintah Targetkan 80% Perempuan dapat Deteksi Dini Kanker Payudara dan Kanker Serviks*.
- Devita, V.T., Hellman S., Rosenberg, S.A. 2008. *Penyunting. Cancer Principles and Practice of Oncology*. Edisi ke-8. Philadelphia. Lippincott William & Wilkins.
- Direktorat Jenderal PP & PL Kementerian Kesehatan. 2013. *Panduan Memperingati Hari Kanker sedunia di Indonesia Tahun 2013*.
- GLOBOCAN. 2012. *Breast Cancer Incidence and Mortality Worldwide in 2012 Summary*.
- Goldhirsch A., Ingle, J.N., Gelber, R.D., Coates, A.S., Thurlimann B., Senn, H.J. 2009. *Thresholds for therapies. highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer*. Annals Oncol, 20, 1319-29.
- Gray, M.J., Gallick, G.E. 2010. *The role of oncogene activation in tumor progression. Mechanisms of oncogene*. USA. Springer, pp:19-22.
- Grushko, T.A., Olopada, O.I. 2008. *Genetic markers in breast tumors with hereditary predisposition: Principle of Molecular Oncology*. 3rd Ed. New Jersey. Humana Press, pp: 85-93.
- Haroon S., Hashmi, Atif Ali, Khurshid, Amna, Kanpurwala, Muhammad Adnan, Mutjuba, Shafaq, Malik, Babar, et al. 2013. *Ki-67 Index in Breast Cancer*.

- Correlation with Other Prognostic Markers and Potential in Pakistani Patients.* Asian Pacific Journal of Cancer Prevention, 14, 4353-4357.
- Inwald, E.C., Klinkhammer-Schalke M., Hofstadter F., Zeman F., Koller M., Gertstenhauer M., et al. 2013. *Ki-67 Is A Prognostic Parameter In Breast Cancer Patients: Results of A Large Population-Based Cohort of A Cancer Registry.* Breast Cancer Res Treat, 139, 539-552.
- Jerjees, D.A., Alabdullah M., Green, A.R., et al. 2014. *Prognostic and Biological Significance of Proliferation and HER2 Expression in the Luminal Class of Breast Cancer.* Breast Cancer Res Treat, 145, pp: 317-330.
- Jeong S., et al. 2011. *Hormone Receptor Status Rather Than HER2 Status is Significantly Associated with Increased Ki-67 and p53 Expression in Triple-negative Breast Carcinomas, and High Expression of Ki-67 but Not p53 is Significantly Associated with Axillary Nodal Metastasis in Triple-negative and High-Grade Non-Triple-Negative Breast Carcinomas.* Am J ClinPathol, 135, 230-237.
- Kontzoglou K., Palla V., Karaolani, G., et al. 2013. *Correlation between Ki67 and Breast Cancer Prognosis.* Oncology: 84:219-225.
- Masuda H., Baggerly, K.A., Wang Y., et al. 2013. *Differential Response to Neoadjuvant Chemotherapy among 7 Triple-negative Breast Cancer Molecular Subtypes.* American Association for Cancer Research.
- Payne, S.J.L., Bowen, R.L., Jones, J.L., & Wells, C.A. 2008. *Predictive markers in breast cancer- the present histopathology,* 52, 82-90.
- Raica M., Jung I., Cimpean, A.M., et al. 2009. *From Conventional Pathologic Diagnosis to the Molecular Classification of Breast Carcinoma: Are We Ready for the Change?.* Romanian Journal of Morphology and Embryology, 50(1), 5-13.
- Revillon F., Bonnetterre J., Peyrat, J.P. 1998. *ERBB2 Oncogene In Human Breast Cancer and It's Clinical Significance.* Eur J Cancer, 34, pp:791-808.
- RumahSakitUmumPendidikan H. Adam Malik Medan, 2015. *Data KasusKeganasanPayudara 2010-2014.* [Unpublished].

- Shokouh, T.Z., Ezatollah, A., Barand, P. 2015. *Interrelationship Between Ki67, HER2/neu, p53, and PR status and Their Associations with Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes*. *Medicine*, 94(32),e11359.
- Suyatno, Pasribu, E.T. 2014.*Bedah Onkologi: Diagnosis dan terapi*.edisi ke-2. Sagung Seto. Jakarta.
- Taneja P., Maglic D., Kai F., Zhu S., Kendig, R.D., Fry, E.A., Inoue K. 2010. *Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance*. *Clinical Medicine Insights*,4,15-34.
- Urruticoechea A., Smith, I.E., Dowsett M. 2005. *Proliferation Marker Ki-67 in Early Breast Cancer*. *J ClinOncol*, 23, pp:7212 –7220.
- WHO. 2014. *Breast Cancer: Prevention and Control*.
- Weigel, M.T., and Dowsett M. 2010.*Review, Current and emerging biomarkers in breast cancer: prognosis and prediction*. *Endocrine- Related Cancer*,17,R245-R262.
- YanagawaM.,IkemotK.,Kawauchi S., et al.2012.*Luminal A and Luminal B (HER2 Negative) Subtypes of Breast Cancer Consist of a Mixture of Tumors with Deifferent Genotype*. *BMC Research Notes*, 376(5).
- Yerushalmi R., Woods R.,Ravdin, P.M.,Hayes, M.M., and Gelmon, K.A.2010. *Ki67 in Breast Cancer : Prognostic and Predictive Potential*. *Lancet Oncol*, 11, 174-183.
- Yersal O., and Barutca S. 2014.*Biological Subtypes of Breast Cancer: Prognostic and Therapeutic Implications*. *World J Clin Oncol*,5(3),412-424.
- Yan J., Liu, X.L., Han, L.Z., et al. 2015.*Relation Between Ki67, ER, PR, Her2/neu, p21, EGFR, and TOPII- α Expression in invasive Ductal Breast Cancer Patients and Correlation with Prognosis*. *Asian Pac J Cancer Prev*, 16(2), 823-829.
- Zhou W.,Jirstrom K.,Amini R.M., et al.2013. *Molecular Subtypes in Ductal Carcinoma in situ of the Breast and Their Relation to Prognosis: a Population-Based Cohort Study*. *BMC Cancer*,13,512.